The biotech said its decision to cut jobs and R&D programs was to consolidate its scattered pipeline and create a more efficient organization.
Due to the cuts, the company has reduced its annual burn rate by 25 percent.
About 80 employees will be affected. The biotech will still employ 200.
“From a position of strength with a healthy balance sheet and a 200-person team, Inovio sharpened its focus to create a more efficient organization with greater financial flexibility and a longer runway,” J.Joseph Kim, PhD, Inovio’s president and CEO said in a news release.
More articles on pharmacy:
Oklahoma opioid trial wraps: 10 takeaways
Drugmaker tried to shred records before FDA inspection, agency claims
New Jersey physician, pharmacy workers charged in $10M kickback scheme
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
